<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2021-7-134-141</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-6140</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДРУГИЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OTHER PROBLEMS OF ENDOCRINOLOGY</subject></subj-group></article-categories><title-group><article-title>Ориентированность в вопросах лечения остеопороза у врачей, работающих в области физической и реабилитационной медицины</article-title><trans-title-group xml:lang="en"><trans-title>Qualification in the field of osteoporosis treatment in doctors working in the field of physical and rehabilitation medicine</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1886-124X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марченкова</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Marchenkova</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марченкова Лариса Александровна - кандидат медицинских наук, ведущий научный сотрудник, заведующая отделом соматической реабилитации, репродуктивного здоровья и активного долголетия.</p><p>121099, Москва, ул. Новый Арбат, д. 32.</p></bio><bio xml:lang="en"><p>Larisa A. Marchenkova - Cand. Sci. (Med.), Leading Research Scientist, Head of Somatic Rehabilitation, Active Longevity and Reproductive Health Department, National Medical Research Center for Rehabilitation and Balneology.</p><p>32, Novyi Arbat St., Moscow, 121099.</p></bio><email xlink:type="simple">MarchenkovaLA@nmicrk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр реабилитации и курортологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Rehabilitation and Balneology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>12</day><month>05</month><year>2021</year></pub-date><volume>0</volume><issue>7</issue><fpage>134</fpage><lpage>141</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Марченкова Л.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Марченкова Л.А.</copyright-holder><copyright-holder xml:lang="en">Marchenkova L.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/6140">https://www.med-sovet.pro/jour/article/view/6140</self-uri><abstract><sec><title>Введение</title><p>Введение. Для пациентов с остеопорозом (ОП) часто требуется назначение реабилитационных мероприятий, поэтому врачи, работающие в области физической и реабилитационной медицины, должны хорошо ориентироваться в этой проблеме.</p></sec><sec><title>Цель</title><p>Цель. Изучить информированность врачей реабилитационной медицины в области диагностики и лечения остеопороза и их активности в оказании медицинской помощи пациентам с ОП.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен анкетный опрос 157 врачей (мужчины - 34, женщины - 123) 8 медицинских специальностей, работающих в 27 специализированных медицинских учреждениях по профилю «медицинская реабилитация». Анкета для врачей состояла из 21 пункта специальных вопросов.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. В выборке врачей-реабилитологов 90,45% опрошенных отметили, что проблема ОП актуальна для их клинической деятельности, 100% врачей указали, что наличие ОП значимо влияет на реабилитационный прогноз и 95,54% -на степень эффективности медицинской реабилитации. По оценке респондентов, пациенты с ОП составляют в среднем 30,0% [20,0; 50,0] (0-90) от общего потока пациентов. Лечением ОП занимаются преимущественно эндокринологи (все опрошенные врачи - 100%), акушеры-гинекологи (66,67%) и терапевты (60%). Наиболее часто специалистами реабилитационных учреждений рекомендуются золедроновая кислота (на это указали 23,57% врачей), препараты витамина D (23,57%) и кальция (14,65%), различные методы лечебной физкультуры (14,65%) и парентеральная форма ибандроновой кислоты (12,74%).</p></sec><sec><title>Выводы</title><p>Выводы. Наличие ОП значимо влияет на реабилитационный прогноз и эффективность медицинской реабилитации. 23,57% специалистов в области реабилитационной медицины назначают пациентам лечение ОП, отдавая предпочтение парентеральным бисфосфонатам, препаратам витамина D и кальция и лечебной физкультуре.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. The special rehabilitation programs are often required for patients with osteoporosis (OP). So physicians working in the field of physical and rehabilitation medicine should be well-versed in this problem.</p></sec><sec><title>Aims</title><p>Aims. To study the awareness of doctors of rehabilitation medicine in the field of diagnosis and treatment of osteoporosis and their activity in providing medical care to patients with OP.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A questionnaire survey of 157 doctors (M-34, F-123) of 8 medical specialties working in 27 specialized medical institutions on the profile of “medical rehabilitation” was carried out. The questionnaire for doctors consisted of 21 items of special questions.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. In the sample of rehabilitation doctors, 90.45% of the interviewed doctors believed that the problem of OP is relevant for their clinical activities, 100% of the respondents indicated that the presence of OP significantly affects the rehabilitation prognosis and 95.54% - on the degree of effectiveness of medical rehabilitation. According to the respondents, patients with OP make up on average 30.0% [20.0; 50.0] (0-90) of the total flow of patients. Endocrinologists (all surveyed doctors - 100%), obstetricians - gynecologists (66.67%) and therapists (60%) are mainly involved in the treatment of OP. Most often, specialists from rehabilitation institutions recommend zoledronic acid (23.57% of doctors indicated in this aspect), preparations of vitamin D (23.57%) and calcium (14.65%), various methods of physical therapy (14.65%) and parenteral form of ibandronic acid (12.74%).</p></sec><sec><title>Conclusions</title><p>Conclusions. The presence of OP significantly affects the rehabilitation prognosis and the effectiveness of medical rehabilitation. 23.57% of specialists in the field of rehabilitation medicine prescribe treatment for OP to patients, giving preference to parenteral bisphosphonates, vitamin D, calcium and physical exercises.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>остеопороз</kwd><kwd>медицинская реабилитация</kwd><kwd>лечение остеопороза</kwd><kwd>золедроновая кислота</kwd><kwd>ибандроновая кислота</kwd><kwd>анкетный опрос</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoporosis</kwd><kwd>medical rehabilitation</kwd><kwd>osteoporosis treatment</kwd><kwd>zoledronic acid</kwd><kwd>ibandronic acid</kwd><kwd>questionnaire survey</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Лесняк О.М., Баранова И.А., Белова К.Ю., Гладкова Е.Н., Евстигнеева Л.П., Ершова О.Б. и др. Остеопороз в Российской Федерации: эпидемиология, медико-социальные и экономические аспекты проблемы (обзор литературы). Травматология и ортопедия России. 2018;24(1):155-168. doi: 10.21823/2311-2905-2018-24-1-155-168.</mixed-citation><mixed-citation xml:lang="en">Lesnyak O.M., Baranova I.A., Belova K.Yu., Gladkova E.N., Evstigneeva L.P., Ershova O.B. et al. Osteoporosis in Russian Federation: Epidemiology, SocioMedical and Economical Aspects (Review). Travmatologiya i ortopediya Rossii = Traumatology and Orthopedics of Russia. 2018;24(1):155-168. (In Russ.) doi: 10.21823/2311-2905-2018-24-1-155-168.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Svedbom A., Hernlund E., Borgstom F., Strom O., Alekna V., Tamulaitiene M. et al. Quality of Life for Up to 18 Months after Low-Energy Hip, Vertebral, and Distal Forearm Fractures - Result from the ICUROS. Osteoporosis Inl. 2018;29(3):557-566. doi: 10.1007/s00198-017-4317-4.</mixed-citation><mixed-citation xml:lang="en">Svedbom A., Hernlund E., Borgstom F., Strom O., Alekna V., Tamulaitiene M. et al. Quality of Life for Up to 18 Months after Low-Energy Hip, Vertebral, and Distal Forearm Fractures - Result from the ICUROS. Osteoporosis Inl. 2018;29(3):557-566. doi: 10.1007/s00198-017-4317-4.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Марченкова Л.А., Макарова Е.В. Изменение показателей качества жизни у женщин с переломами позвонков на фоне остеопороза и возможности их коррекции с помощью нового комплекса реабилитации с включением технологий механотерапии. Вестник восстановительной медицины. 2020;99(5):70-78. doi: 10.38025/2078-1962-2020-99-5-70-78.</mixed-citation><mixed-citation xml:lang="en">Marchenkova L.A., Makarova E.V. Quality of Life Changes in Women with Osteoporotic Vertebral Fractures and Possibility of Its Improvement Using New Complex of Physical therapy Including Mechanotheraputic technologies. Vestnik vosstanovitel'noy meditsiny = Bulletin of Rehabilitation Medicine. 2020;99(5):70-78. (In Russ.) doi: 10.38025/2078-1962-2020-99-5-70-78.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Марченкова Л.А., Макарова Е.В., Герасименко М.Ю. Оценка риска остеопоротических переломов и распространенности остеопороза у пациентов в возрасте 50 лет и старше, проходящих медицинскую реабилитацию. Физиотерапия, бальнеология и реабилитация. 2020;19(1):13-19. doi: 10.17816/1681-3456-2020-19-1-2.</mixed-citation><mixed-citation xml:lang="en">Marchenkova L.A., Makarova E.V., Gerasimenko M.Yu. Assesment of Osteoporotic Fractures Risk and Osteoporosis Prevalence among Patients over 50 Years Old Undergoing Medical Rehabilitation. Fizioterapiya, bal'neologiya i reabilitatsiya = Russian Journal of Physiotherapy, Balneology and Rehabilitation. 2020;19(1):13-19. (In Russ.) doi: 10.17816/1681-3456-2020-19-1-2.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Буйлова Т.В., Марченкова Л.А. Мультидисциплинарный подход к реабилитации пациентов с остеопорозом (обзор литературы). Вопросы курортологии, физиотерапии и лечебной физической культуры. 2020;97(2):58-67. doi: 10.17116/kurort20209702158.</mixed-citation><mixed-citation xml:lang="en">Builova T.V., Marchenkova L.A. Multidisciplinary Approach to the Rehabilitation of Patients with Osteoporosis. Voprosy kurortologii, fizi-oterapii i lechebnoy fizicheskoy kul'tury = Problems of Balneology, Physiotherapy, and Exercise Therapy. 2020;97(2):58-67. (In Russ.) doi: 10.17116/kurort20209702158.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Марченкова Л.А., Макарова Е.В. Эффективные возможности комплексной реабилитации пациентов с переломами на фоне остеопороза. РМЖ. 2018;26(4-1):10-14. Режим доступа: https://www.rmj.ru/articles/revmatologiya/Effektivnye_vozmoghnosti_kompleksnoy_reabilitacii_pacientov_s_perelomami_na_fone_osteoporoza.</mixed-citation><mixed-citation xml:lang="en">Marchenkova L.A., Makarova E.V. Effective Possibilities of Complex Rehabilitation in Patients with Fractures on the Background of Osteoporosis. RMZH = RMJ. 2018;26(4-1):10-14. (In Russ.) Available at: https://www.rmj.ru/articles/revmatologiya/Effektivnye_vozmoghnosti_kompleksnoy_reabilitacii_pacientov_s_perelomami_na_fone_osteoporoza.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Марченкова Л.А., Древаль А.В., Крюкова И.В. Информированность врачей разных специальностей в области остеопороза в Московском регионе. Остеопороз и остеопатии. 2012;15(1):11-14. doi: 10.14341/osteo2012111-14.</mixed-citation><mixed-citation xml:lang="en">Marchenkova L.A., Dreval' A.V., Kryukova I.V. Awareness of Physicians of Various Specialties of Osteoporosis in Moscow Region. Osteoporoz i osteo-patii = Osteoporosis and Bone Diseases. 2012;15(1):11-14. (In Russ.) doi: 10.14341/osteo2012111-14.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Древаль А.В., Марченкова Л.А., Григорьева Е.А. Оценка качества диагностики постменопаузального остеопороза в Московской области по данным анкетного опроса пациентов. Проблемы эндокринологии. 2012;(1):23-28. doi: 10.14341/probl201258123-28/.</mixed-citation><mixed-citation xml:lang="en">Dreval' A.V., Marchenkova L.A., Grigor'eva E.A. The estimation of the Quality of Diagnostics of Post-Menopausal Osteoporosis in the Moscow Region from the Results of a Questionnaire Study. problemy endokrinologii = Problems of Endocrinology. 2012;(1):23-28 (In Russ.) doi: 10.14341/probl201258123-28.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Марченкова Л., Древаль А., Крюкова И., Добрицына М., Саркисова А. Оценка медицинской помощи больным остеопорозом по результатам анкетирования врачей Московской области. Врач. 2009;(11):95-102. Режим доступа: https://elibrary.ru/item.asp?id=13029441.</mixed-citation><mixed-citation xml:lang="en">Marchenkova L., Dreval' A., Kryukova I., Dobritsyna M., Sarkisova A. Assessment of Medical Care to Osteoporotic Patients from the Result of Questionnaire Survey among Physicians from the Moscow Region. Vrach = The Doctor. 2009;(11):95-102. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=13029441.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Марченкова Л.А., Древаль А.В., Крюкова И.В. Влияние тематического обучения на информированность и профессиональную мотивацию врачей в области остеопороза. Профилактическая медицина. 2012;15(6):29-35. Режим доступа: https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2012/6/downloads/ru/031726-6130201266.</mixed-citation><mixed-citation xml:lang="en">Marchenkova L.A., Dreval' A.V., Kryukova I.V. Impact of Subject Education on the Awareness and Professional Motivation of Physicians in the Field of Osteoporosis. Profilakticheskaya meditsina = The Russian Journal of Preventive Medicine. 2012;15(6):29-35. (In Russ.) Available at: https://mediasphera.ru/issues/profilakticheskaya-meditsina/2012/6/downloads/ru/031726-6130201266.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Белая Ж.Е., Рожинская Л.Я., Гребенникова Т.А., Kanis J.A., Пигарова Е.А., Родионова С.С. и др. Краткое изложение проекта федеральных клинических рекомендаций по остеопорозу. Остеопороз и остеопатии. 2020;23(2):4-21. doi: 10.14341/osteo12710.</mixed-citation><mixed-citation xml:lang="en">Belaya Z.E., Rozhinskaya L.Y., Grebennikova T.A., Kanis J.A., Pigarova E.A., Rodionova S.S. et al. Summary of the Draft Federal Clinical Guidelines for Osteoporosis. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2020;23(2):4-21. (In Russ.) doi: 10.14341/osteo12710.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Laliberte M.-C., Perreault S., Jouini G., Shea BJ., Lalonde L. Effectiveness of Interventions to Improve the Detection and Treatment of Osteoporosis in Primary Care Settings: A Systematic Review and Meta-Analysis. Osteoporosis Int. 2011;22(11):2743-2768. doi: 10.1007/s00198-011-1557-6.</mixed-citation><mixed-citation xml:lang="en">Laliberte M.-C., Perreault S., Jouini G., Shea B.J., Lalonde L. Effectiveness of Interventions to Improve the Detection and Treatment of Osteoporosis in Primary Care Settings: A Systematic Review and Meta-Analysis. Osteoporosis Int. 2011;22(11):2743-2768. doi: 10.1007/s00198-011-1557-6.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007;356(18):1809-1822. doi: 10.1056/NEJMoa067312.</mixed-citation><mixed-citation xml:lang="en">Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007;356(18):1809-1822. doi: 10.1056/NEJMoa067312.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Black D.M., Reid I.R., Boonen S., Bucci-Rechtweg C., Cauley J.A., Cosman F. et al. The Effect of 3 versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-254. doi: 10.1002/jbmr.1494.</mixed-citation><mixed-citation xml:lang="en">Black D.M., Reid I.R., Boonen S., Bucci-Rechtweg C., Cauley J.A., Cosman F. et al. The Effect of 3 versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-254. doi: 10.1002/jbmr.1494.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C. et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. New Engl J Med. 2007;357(18):1799-1809. doi: 10.1056/NEJMoa074941.</mixed-citation><mixed-citation xml:lang="en">Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C. et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. New Engl J Med. 2007;357(18):1799-1809. doi: 10.1056/NEJMoa074941.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chesnut C.H. 3rd, Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A. et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res. 2004;19(8):1241-1249. doi: 10.1359/JBMR.040325.</mixed-citation><mixed-citation xml:lang="en">Chesnut C.H. 3rd, Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A. et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res. 2004;19(8):1241-1249. doi: 10.1359/JBMR.040325.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bauss F., Schimmer R.C. Ibandronate: The First Once-Monthly Oral Bisphosphonate for Treatment of Postmenopausal Osteoporosis. Ther Clin Risk Manag. 2006;2(1):3-18. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661644/.</mixed-citation><mixed-citation xml:lang="en">Bauss F., Schimmer R.C. Ibandronate: The First Once-Monthly Oral Bisphosphonate for Treatment of Postmenopausal Osteoporosis. Ther Clin Risk Manag. 2006;2(1):3-18. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661644/.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cranney A., Wells G., Yetisir E., Adami S., Cooper C., Delmas P.D. et al. Ibandronate for the Prevention of Nonvertebral Fractures: A Pooled Analysis of Individual Patient Data. Osteoporosis Int. 2009;20(2):291-297. doi: 10.1007/s00198-008-0653-8.</mixed-citation><mixed-citation xml:lang="en">Cranney A., Wells G., Yetisir E., Adami S., Cooper C., Delmas P.D. et al. Ibandronate for the Prevention of Nonvertebral Fractures: A Pooled Analysis of Individual Patient Data. Osteoporosis Int. 2009;20(2):291-297. doi: 10.1007/s00198-008-0653-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Bianchi G., Czerwinski E., Kenwright A., Burdeska A., Recker R.R., Felsenberg D. Long-Term Administration of Quarterly IV Ibandronate Is Effective and Well Tolerated in Postmenopausal Osteoporosis: 5-Year Data from the DIVA Study Long-Term Extension. Osteoporosis Int. 2012;23(6):1769-1778. doi: 10.1007/s00198-011-1793-9.</mixed-citation><mixed-citation xml:lang="en">Bianchi G., Czerwinski E., Kenwright A., Burdeska A., Recker R.R., Felsenberg D. Long-Term Administration of Quarterly IV Ibandronate Is Effective and Well Tolerated in Postmenopausal Osteoporosis: 5-Year Data from the DIVA Study Long-Term Extension. Osteoporosis Int. 2012;23(6):1769-1778. doi: 10.1007/s00198-011-1793-9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Recker R.R., Ste-Marie L.G., Langdahl B., Czerwinski E., Bonvoisin B., Masanauskaite D. et al. Effects of Intermittent Intravenous Ibandronate Injections on Bone Quality and Micro-Architecture in Women with Postmenopausal Osteoporosis: The DIVA Study. Bone. 2010;46(3):660-665. doi: 10.1016/j.bone.2009.11.004.</mixed-citation><mixed-citation xml:lang="en">Recker R.R., Ste-Marie L.G., Langdahl B., Czerwinski E., Bonvoisin B., Masanauskaite D. et al. Effects of Intermittent Intravenous Ibandronate Injections on Bone Quality and Micro-Architecture in Women with Postmenopausal Osteoporosis: The DIVA Study. Bone. 2010;46(3):660-665. doi: 10.1016/j.bone.2009.11.004.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
